11:55 AM
 | 
Jul 13, 2018
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Cold Harbor JV developing copper chelator for Wilson's disease

DepYmed Inc., a joint venture between Cold Spring Harbor Laboratory and Ohr Pharmaceutical Inc. (NASDAQ:OHRP), is developing its protein tyrosine phosphatase 1B (PTP-1B; PTPN1) inhibitor DPM-1001 as a copper chelator for Wilson's disease. In a Genes & Development study, Cold Spring Harbor researchers showed the compound reduced disease-associated copper levels and cell damage.

Wilson's disease is characterized by liver and brain deficits from accumulation of copper caused by mutations in ATPase Cu++ transporting beta polypeptide (ATP7B).

The Cold Spring Harbor team found DPM-1001 increased cell viability in skin fibroblasts from six Wilson's...

Read the full 444 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >